Featured Research Search Results

Testing a KRAS Vaccine with Immunotherapy for Advanced Pancreatic and Colorectal Cancers with MMR‑Proficient (MMR‑p) Tumors

Clinicaltrials.gov identifier:
NCT06411691

Treatment
Phase 1b treatment study for previously-treated pancreatic or colorectal cancer with a KRAS mutation

Phase 1

A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)

Clinicaltrials.gov identifier:
NCT04294927

Prevention
Prevention study for women at high risk for ovarian cancer

Comparing Hormone Therapy With and Without Chemotherapy for Premenopausal Breast Cancer (OFSET)

Clinicaltrials.gov identifier:
NCT05879926

Treatment
Study for premenopausal, early-stage, ER positive, HER2-negative breast cancer

Phase 3

Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab

Clinicaltrials.gov identifier:
NCT05112601

Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker

Phase 2

Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT05384535

Prevention
Screening for people at high risk for prostate cancer

The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

Clinicaltrials.gov identifier:
NCT05926102

Prevention
Prostate cancer screening study for male US veterans age 55–69

Understanding Access to Genetic Services for Latina Women with Breast Cancer

Surveys, Registries, Interviews
A phone survey for Latina breast cancer survivors diagnosed within the past five years in California

Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

Clinicaltrials.gov identifier:
NCT05372640

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Phase 1

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Phase 1

Post-surgery Immunotherapy (Toripalimab) for MMR-D / MSI-H Stage IIB-III Colon Cancer

Clinicaltrials.gov identifier:
NCT07140679

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

Phase 2

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD

Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT06958328

Treatment
Radiation treatment study for people with locally advanced pancreatic cancer

Phase 3

A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer

Clinicaltrials.gov identifier:
NCT06952803

Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer

Phase 3

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations

Clinicaltrials.gov identifier:
NCT04890613

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Phase 1

PREVAIL Study: A Genetic Education and Genetic Testing Study for African American Men with Prostate Cancer or with a Strong Family History of Cancer

Surveys, Registries, Interviews
Study for African American men with prostate cancer or with a strong family history of cancer

Understanding the Cancer Journey: A Survey of Patient Experiences and Emotional Impact

Surveys, Registries, Interviews
Survey for people diagnosed with lung, liver, pancreatic or thyroid cancer

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

Phase 3

Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs

Clinicaltrials.gov identifier:
NCT06167317

Treatment
Treatment study for people with advanced or metastatic solid tumors

Phase 1